



(51) International Patent Classification:
A61K 31/519 (2006.01) *C07D 513/04* (2006.01)

(21) International Application Number:
PCT/US2024/038216

(22) International Filing Date:
16 July 2024 (16.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/514,089 17 July 2023 (17.07.2023) US
63/655,384 03 June 2024 (03.06.2024) US

(71) Applicant: **KURA ONCOLOGY, INC.** [US/US]; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US).

(72) Inventors: **BAKALE, Roger Paul**; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US). **BOWE, Craig Michael**; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US). **SENGUPTA, Dipanjan**; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US). **ANDRES, Patricia**; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US). **DENG, Xi-**

aohu; 12730 High Bluff Drive, Suite 400, San Diego, California 92130 (US).

(74) Agent: **WORMALD, Michael** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: CRYSTALLINE FORMS OF A MENIN INHIBITOR




FIGURE 1

(57) Abstract: Described herein are crystalline forms of (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile or solvate thereof.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*